Clinical trials: IBM
Inclusion Body Myositis, Sporadic
Ruxolitinib Treatment in Inclusion Body Myositis
Refer to the "Detailed Description" section.
- Trial name
- BIGTIM (NCT06536166)
- Testing
- Ruxolitinib
- Where
- 21 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Inclusion Body Myositis, Myotonic Dystrophy 1
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
The planned project is an intervention study to assess the risk of falling after adaptation of an assistive gait devices in patients with the following neuromuscular diseases: Inclusion body myositis, myotonic dystrophy, limb…
- Conditions
- Inclusion Body Myositis, Myotonic Dystrophy 1, Myotonic Dystrophy 2, Facio-Scapulo-Humeral Dystrophy
- Trial name
- Risk of fall (NCT07072676)
- Testing
- Assistive gait devices combined with physiotherapy
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- LMU Klinikum
Inclusion Body Myositis
Lithium in Inclusion Body Myositis (IBM)
IBM is the most common acquired muscle disease occurring over the age of 50. The underlying cause remains unknown and there is currently no effective treatment.
- Trial name
- Li-IBM (NCT00917956)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Phoenix Neurological Associates, LTD
Muscle Diseases
Acceptance and Commitment Therapy for Muscle Disease
In adults, muscle diseases are usually chronic long-term conditions that do not have a definitive cure. Supportive care has been shown to reduce complications from muscle disease and improved survival in some cases.
- Trial name
- ACTMuS (NCT02810028)
- Testing
- Acceptance and Commitment Therapy (ACT)
- Where
- United Kingdom
- Volunteers
- 155 people
- Sponsor
- King's College Hospital NHS Trust
Inclusion Body Myositis
IBM Dietary Surveillance Study
The goal of this observational study is to understand how diet may influence the disease characteristics of inclusion body myositis (IBM).
- Trial name
- NCT07535996
- Testing
- Whole-Body Dual-Energy X-ray Absorptiometry, Anthropometry, Capillary Blood Sampling
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Manchester Metropolitan University
Sporadic Inclusion Body Myositis
Blood-flow Restricted Exercise in Inclusion Body Myositis
This study evaluates the effects of a low-intensity blood-flow restricted exerciser protocol on patient reported physical function, in patients with sporadic inclusion body myositis.
- Trial name
- NCT02317094
- Testing
- Blood-flow restricted training, Care as usual
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- University of Southern Denmark
Dermatomyositis, Inclusion Body Myositis
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
Inflammatory myopathies are a group of muscle diseases characterized by muscle weakness, high levels of muscle enzymes in the blood, and inflammation of the tissue surrounding muscle fibers (endomysium).
- Conditions
- Dermatomyositis, Inclusion Body Myositis, Polymyositis
- Trial name
- NCT00001261
- Testing
- Gamma Globulin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Myositis
Investigating Genes in Patients With Polymyositis and Dermatomyositis
Polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM)belong to a group of inflammatory muscle disorders, of unknown cause, that are characterised by skeletal muscle inflammation and progressive muscular…
- Trial name
- UKMYONET (NCT01171573)
- Testing
- Venepuncture
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Northern Care Alliance NHS Foundation Trust
Inclusion Body Myositis (IBM)
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study…
- Trial name
- NCT06450886
- Testing
- Ulviprubart (ABC008)
- Where
- 21 sites in United States, Australia
- Volunteers
- 270 people
- Sponsor
- Abcuro, Inc.
IBM, Inclusion Body Myositis
Establishing Muscle Impedance Parameters With Electrical Impedance Myography
The primary aim of this study is to assess the changes in the impedance parameters of muscles in inclusion body myositis (IBM) through electrical impedance myography (EIM), an emerging non-invasive electrodiagnostic technology.
- Trial name
- NCT03633318
- Testing
- electrical impedance myography (EIM)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Yale University
Sporadic Inclusion Body Myositis
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic…
- Trial name
- RESILIENT (NCT01925209)
- Testing
- BYM338/bimagrumab
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Inclusion Body Myositis
Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Inclusion-Body Myositis (IBM) results in weakness and the deterioration of distal arm muscles, the symptoms of which are currently assessed through expert examination at clinical visits.
- Trial name
- NCT06153108
- Testing
- PAMSys pendant PAMSys wrist sensors
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Sporadic, Inclusion Body
Immune Abnormalities in Sporadic Inclusion Body Myositis
This study will examine the abnormal immune response in patients with sporadic inclusion body myositis (s-IBM)-the most common inflammatory muscle disease in people over the age of 50.
- Conditions
- Sporadic, Inclusion Body, Myositis
- Trial name
- NCT00030212
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Sporadic Inclusion Body Myositis
Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study
Sporadic inclusion body myositis (sIBM) is a rare idiopathic inflammatory myopathy characterized by chronic proximal leg and distal arm asymmetric muscle weakness.
- Trial name
- NCT02735447
- Volunteers
- 190 people
- Sponsor
- La-ser Europe Limited
Breast Cancer, Lung Cancer
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer
- Trial name
- NCT02565017
- Testing
- Focus groups
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dermatomyositis, Polymyositis
Adult and Juvenile Myositis
This study will evaluate subjects with adult- and childhood-onset myositis to learn more about their cause and the immune system changes and medical problems associated with them.
- Conditions
- Dermatomyositis, Polymyositis, Inclusion Body Myositis
- Trial name
- NCT00017914
- Where
- 4 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Sporadic Inclusion Body Myositis (sIBM)
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
This study is an open-label, long-term study for those patients who participated in the prior proof-of-concept protocol, in which the preliminary efficacy for BYM338 in patients with sIBM was demonstrated after a single 30 mg/kg…
- Trial name
- BYM338 (NCT02250443)
- Testing
- BYM338 (Bimagrumab)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Myositis, Polymyositis
Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Idiopathic inflammatory myopathies (IIM) are a great concern in acquired muscle illnesses. An appropriate and rapid diagnosis is necessary, because morbidity and mortality are high and a specific treatment is needed.
- Conditions
- Myositis, Polymyositis, Dermatomyositis, Myositis, Inclusion Body
- Trial name
- DARWIM (NCT01432613)
- Testing
- MRI-oriented muscle biopsy
- Where
- France
- Volunteers
- 139 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD).
- Conditions
- Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome
- Trial name
- NCT07478172
- Testing
- Whole-body Electrical Muscle Stimulation Exercise
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Missouri-Columbia